Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP)

被引:7
作者
Kaplan, Frederick S. [1 ,2 ,3 ]
Al Mukaddam, Mona [2 ,3 ,5 ]
Pignolo, Robert J. [4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Perelman Sch Med, Ctr Res FOP & Related Disorders, Philadelphia, PA 19104 USA
[4] Mayo Clin, Sch Med, Dept Med, Rochester, MN 55905 USA
[5] Penn Med Univ City, Ctr Res FOP & Related Disorders, 3737 Market St,3rd Floor, Philadelphia, PA USA
关键词
Fibrodysplasia ossificans progressiva; Heterotopic ossification; ACVR1; Joint function; Patient-reported outcomes; HETEROTOPIC OSSIFICATION; NATURAL-HISTORY;
D O I
10.1016/j.bone.2017.06.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling genetic disorder characterized by episodic soft tissue swelling (flare-ups) that leads to progressive heterotopic ossification and restricted joint mobility. Methods: Here we present the first longitudinal patient-reported mobility assessment (PRMA) in FOP based on a simple evaluation tool. At initial presentation and follow-up (1-11 year span; median: 6 year span), 64 patients (36 females; 28 males) with classic FOP completed a questionnaire designed to rapidly assess mobility at 15 sites (three axial; six upper limb, and six lower limb). In order to validate this instrument, twenty-one of 64 patients (33%) underwent a cumulative analogue joint involvement scale (CAJIS) evaluation by two physicians within six months of their second self-assessment. Results: We found that: 1) mobility changes were episodic and regional, occurring first in the neck and trunk, followed by the upper limbs and finally the lower limbs; 2) interval improvements in mobility did occur, most notably in the lower limbs (18%), and less so in the upper limbs (12%) and trunk (3%), and 3) patient-reported mobility assessments correlate highly (R-2 = 0.81) with physician-reported CAJIS evaluations. Conclusion: This is the first longitudinal PRMA in FOP and provides a simple and valid tool that can be used in the design and evaluation of clinical trials in this progressively disabling disease. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:158 / 161
页数:4
相关论文
共 12 条
[1]   Patient-reported outcomes: pathways to better health, better services, and better societies [J].
Black, N. ;
Burke, L. ;
Forrest, C. B. ;
Sieberer, U. H. Ravens ;
Ahmed, S. ;
Valderas, J. M. ;
Bartlett, S. J. ;
Alonso, J. .
QUALITY OF LIFE RESEARCH, 2016, 25 (05) :1103-1112
[2]   THE NATURAL-HISTORY OF HETEROTOPIC OSSIFICATION IN PATIENTS WHO HAVE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - A STUDY OF 44 PATIENTS [J].
COHEN, RB ;
HAHN, GV ;
TABAS, JA ;
PEEPER, J ;
LEVITZ, CL ;
SANDO, A ;
SANDO, N ;
ZASLOFF, M ;
KAPLAN, FS .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1993, 75A (02) :215-219
[3]  
Kaplan F. S., 2017, BONE IN PRESS
[4]   From mysteries to medicines: drug development for fibrodysplasia ossificans progressiva [J].
Kaplan, Frederick S. ;
Pignolo, Robert J. ;
Shore, Eileen M. .
EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (08) :637-649
[5]   The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling [J].
Kaplan, Frederick S. ;
Pignolo, Robert J. ;
Shore, Eileen M. .
CYTOKINE & GROWTH FACTOR REVIEWS, 2009, 20 (5-6) :399-407
[6]  
Kaplan Frederick S, 2009, Hum Mutat, V30, P379, DOI 10.1002/humu.20868
[7]   The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment [J].
Pignolo, Robert J. ;
Bedford-Gay, Christopher ;
Liljesthroem, Moira ;
Durbin-Johnson, Blythe P. ;
Shore, Eileen M. ;
Rocke, David M. ;
Kaplan, Frederick S. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (03) :650-656
[8]  
Pignolo RJ, 2013, PEDIATR ENDOCR REV P, V10, P437
[9]  
ROCKE DM, 1994, CLIN ORTHOP RELAT R, P243
[10]   A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva [J].
Shore, EM ;
Xu, MQ ;
Feldman, GJ ;
Fenstermacher, DA ;
Brown, MA ;
Kaplan, FS .
NATURE GENETICS, 2006, 38 (05) :525-527